Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Janux Therapeutics (JANX) Long-Term Debt Issuances (2020 - 2021)

Janux Therapeutics (JANX) has disclosed Long-Term Debt Issuances for 2 consecutive years, with $68.8 million as the latest value for Q2 2021.

  • On a quarterly basis, Long-Term Debt Issuances changed N/A to $68.8 million in Q2 2021 year-over-year; TTM through Mar 2022 was $68.8 million, a N/A change, with the full-year FY2021 number at $124.8 million, changed N/A from a year prior.
  • Long-Term Debt Issuances was $68.8 million for Q2 2021 at Janux Therapeutics, up from $56.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $68.8 million in Q2 2021 to a low of -$4.5 million in Q4 2020.